The authors investigated in vitro and in subcutaneous and spontaneous mouse models the effects of combining enzalutamide and GSK-126, a drug inhibiting the epigenetic modulator EZH2.
[Epigenomics]
Combined Therapy Targeting AR and EZH2 Curbs Castration-Resistant Prostate Cancer Enhancing Anti-Tumor T-cell Response
